Decision-IQ: Assessing Risk and Preventing Tumor Lysis Syndrome
WebcastFaculty
OVERVIEW
Decision-IQ: Assessing Risk and Preventing Tumor Lysis Syndrome is organized by Med-IQ and will be held from Jun 15, 2018 - Jun 14, 2019.
The target audience for this medical event is hematologist/oncologists and medical oncologists. This CME Conference has been approved for a maximum of 0.25 AMA PRA Category 1 Credits.
Course Description:
This brief case-based, digital CME activity incorporates current evidence-based prophylaxis algorithms to assess the risk of tumor lysis syndrome (TLS) in a patient with chronic lymphocytic leukemia (CLL) undergoing anticancer therapy. Links to relevant literature and expert insights are provided to help clinicians prevent and manage TLS.
Course Objectives:
• Implement evidence-based prophylaxis algorithms to mitigate the risk of TLS in patients undergoing potent anticancer therapy
Additional details will be posted as soon as they are available.
The target audience for this medical event is hematologist/oncologists and medical oncologists. This CME Conference has been approved for a maximum of 0.25 AMA PRA Category 1 Credits.
Course Description:
This brief case-based, digital CME activity incorporates current evidence-based prophylaxis algorithms to assess the risk of tumor lysis syndrome (TLS) in a patient with chronic lymphocytic leukemia (CLL) undergoing anticancer therapy. Links to relevant literature and expert insights are provided to help clinicians prevent and manage TLS.
Course Objectives:
• Implement evidence-based prophylaxis algorithms to mitigate the risk of TLS in patients undergoing potent anticancer therapy
Additional details will be posted as soon as they are available.
SPECIALITIES
OncologyHematology Blood and Marrow Transplant
Quick Links